The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

Latest move to cut funding for vaccines is not down to US health secretary. It is part of Trump’s wider war on science.

Doting father-of-two John O'Neill from Althorne, Essex, had a one in 50,000 reaction to the AstraZeneca jab in May 2021 that ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The expiration of Viatris’s EpiPen patent in September 2025 will likely result in increased competition and lower costs in ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

With a 5.98% market share, India is the fourth-largest pharmaceutical supplier to the U.S., behind Ireland, Switzerland, and ...

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th ...